Priya Singhal
Corporate Officer/Principal bei BIOGEN INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Priya Singhal is currently the Chief Medical Officer at Biogen, Inc. She previously worked as the Head-Medical Affairs & Vice President at Vertex Pharmaceuticals, Inc. from 2008 to 2012.
She also held a position as the Head-Research & Development at Zafgen, Inc. Dr. Singhal holds a doctorate degree from the University of Mumbai and a graduate degree from Harvard T.H.
Chan School of Public Health.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOGEN INC.
0,00% | 02.04.2024 | 4 886 ( 0,00% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Priya Singhal
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 02.10.2023 |
Ehemalige bekannte Positionen von Priya Singhal
| Unternehmen | Position | Ende |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Chief Tech/Sci/R&D Officer | 01.01.2012 |
| LARIMAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Priya Singhal
| University of Mumbai | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| BIOGEN INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
